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system. Twenty-four women with FMS, based on the American College of Rheumatology classification
criteria for FMS, and 17 age-matched healthy women were included in the study. Eleven of the patients
with FMS met the DSM-V criteria for major depressive disorder (MDD) [1] (current and past depressive
episode). A slot machine task validated by Martin-Soelch et al. [2], which has been shown to reliably
induce equilibrium and task-related changes in raclopride binding, was used to measure endogenous DA
release in response to unpredictable rewards. PET examinations were performed on a full ring PET/com-
puterized tomography (CT) scanner with a 15.3-cm axial field of view in 3-dimensional mode (Discovery
DSTX, GE Healthcare, Waukesha, WI, USA), at the Department of Nuclear Medicine, University Hos-
pital Zurich, Switzerland. The emission data were corrected for attenuation, scatter, random, and dead
time using the corresponding CT (120 kV/80 mA), and reconstructed using filtered back projection.
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 Letter to the Editor 
lowed by a maintenance infusion over the remainder of the scan-
ning session (a total of 90 min), using a computer-operated pump 
(Arcomed, Syramed SP600, Regensdorf, Switzerland). Dynamic 
emission scanning (41 frames of 0–6,000 s; 100-min scan; framed 
as 4 × 15, 8 × 30, 9 × 60, 2 × 180, 4 × 300, 6 × 200, and 8 × 300 s) 
was initiated with injection of the [ 11 C]raclopride bolus. The re-
gional DA D2/3 nondisplaceable binding potential (BP ND ) was 
measured in the resting state, in all participants, 1 week before the 
reward study.
 Each participant underwent MRI on a 3-T Philips Achieva 
Scanner (Philips Medical Systems, Best, The Netherlands), in order 
to acquire a high-resolution T1-weighted magnetic resonance scan 
(3-D fast-field echo, 160 slices, 1 mm isotropic resolution, repeti-
tion time: 18 ms, echo time: 10 ms, flip angle: 30°) for comparison 
with PET images. All images were checked for structural abnor-
malities and lesions by a clinical neuroradiologist. PMOD software 
version 3.2 (PMOD Technologies Ltd., Zurich, Switzerland) was 
used for PET data analyses. The realigned frames acquired during 
the first 8 min of scanning were summed to generate an image that 
corresponded to the relevant MR image, using PMOD software. 
The transformation matrix was applied to the composite images 
consisting of (i) the baseline (frames acquired at 40–50 min) and 
(ii) reward condition (frames acquired at 60–80 min). These im-
ages were acquired under equilibrium conditions as participants 
performed the sensorimotor control and monetary reward task, 
similarly to the protocol used by Martin-Soelch et al.  [2] . Mean tis-
sue radioactivity concentrations from the baseline and reward im-
ages were extracted using MRI-based regions of interest (ROIs) in 
the anteroventral striatum, ventral putamen, dorsal putamen, mid-
dle caudate, dorsal caudate, nucleus accumbens, and cerebellum, 
similarly to previous research by Drevets et al.  [4] . The mean radio-
activity in a reference region (cerebellum: c’) was used to control 
for the effects of free and nonspecifically bound [ 11 C]raclopride. 
The [ 11 C]raclopride binding potential (BP), which is inversely cor-
related with endogenous DA release, was selected as our measure-
ment of D2 receptor binding in each brain region. The percentage 
in [ 11 C]raclopride binding was computed as the difference in BP ND 
between baseline and reward images, similarly to the protocol de-
scribed by Watabe et al.  [3] . Negative values of [ 11 C]raclopride ΔBP 
indicated the percentage of [ 11 C]raclopride displacement by en-
dogenously released DA. Greater negative values indicate greater 
[ 11 C]raclopride displacement. One-sample  t tests were used to test 
the significance of ΔBP in each region and each group. The findings 
were corrected for multiple comparisons using Bonferroni correc-
tion (significance threshold set at α = 0.005) for 2-tailed  p  values. 
The a priori hypothesis was tested using 1-way ANOVA with group 
as a factor for the ΔBP  obtained in the striatal ROIs. Since age is 
known to influence D2/D3 receptor BP, this factor was included as 
covariate in the analysis. Significant group effects indicated by the 
ANOVA were further tested using the Gabriel post hoc test.
 In additional analyses with the covariates severity of depressive 
symptoms, FMS duration, and antidepressant medication, no cor-
relations were found with BP ND in any striatal regions. 
 Dear Editor, 
 We herein report results of our pilot study using bolus-plus-
infusion [ 11 C]raclopride positron emission tomography (PET) 
scanning to assess endogenous dopamine (DA) release associated 
with unpredictable monetary rewards in patients with fibromyal-
gia syndrome (FMS) and healthy controls. The aim of this project 
was to investigate whether FMS was associated with a dysfunction 
of the central reward system.
 Twenty-four women with FMS, based on the American College 
of Rheumatology classification criteria for FMS, and 17 age-
matched healthy women were included in the study. Eleven of the 
patients with FMS met the DSM-V criteria for major depressive 
disorder (MDD)  [1] (current and past depressive episode). A slot 
machine task validated by Martin-Soelch et al.  [2] , which has been 
shown to reliably induce equilibrium and task-related changes in 
raclopride binding, was used to measure endogenous DA release in 
response to unpredictable rewards. PET examinations were per-
formed on a full ring PET/computerized tomography (CT) scanner 
with a 15.3-cm axial field of view in 3-dimensional mode (Discov-
ery DSTX, GE Healthcare, Waukesha, WI, USA), at the Depart-
ment of Nuclear Medicine, University Hospital Zurich, Switzer-
land. The emission data were corrected for attenuation, scatter, 
random, and dead time using the corresponding CT (120 kV/80 
mA), and reconstructed using filtered back projection. [ 11 C]Raclo-
pride (415 ± 30 MBq) was administered as an initial bolus over
60 s, according to the protocol described by Watabe et al.  [3] , fol-
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 The study was approved by the Ethical Committee of the Can-
ton Zurich and the Swiss Federal Department of Health, in accor-
dance with the current version of the Declaration of Helsinki and 
the Swiss regulatory requirements. 
 We found unexpectedly significant reductions in D2/D3 recep-
tor BPs in the reward versus the control condition in the right 
nucleus accumbens and caudate nucleus in both FMS groups com-
pared to controls, which may indicate increased DA release ( Fig. 1 ). 
The effects in the right nucleus accumbens were more prominent 
in patients with FMS and comorbid depression (41.1%) compared 
to healthy controls (23.3%;  p <  0.01). Reductions in the right cau-
date nucleus of patients with FMS were also greater in patients with 
comorbid depression (24.6%) compared to patients without de-
pression (13.4%;  p <  0.02). The differences in percentage displace-
ment observed between groups suggest differences in the neural 
processing of rewards as measured by the DA release associated 
with unpredictable rewards. Our findings in patients with FMS 
and MDD are not in line with previous attempts at elucidating the 
striatal response to reward in individuals with MDD  [5, 6] . The 
finding that the DA response to rewarding stimuli increased in 
patients with FMS and comorbid depression is novel. One possible 
explanation for the accentuated DA reaction in our patients with 
FMS may be an upregulation of the mesolimbic DA system, which 
occurs due to underactivation of the striatal and prefrontal DA 
projections to the mesolimbic DA system. Another possibility is 
that chronic exposure to stress from persistent pain may have af-
fected the DA response in our patients with FMS; recent animal 
studies have provided evidence that repeated exposure to stress can 
affect both tonic and phasic DA release in the nucleus accumbens 
and medial prefrontal cortex  [7] .
 Our findings extend previous research on chronic pain-related 
impairments in reward processing  [8, 9] and show that patients 
with FMS and depression can be distinguished from those without 
depression on a neurobiological level. Furthermore, the finding 
that FMS patients with and without MDD exhibited different DA 
release patterns has important implications for identifying distinct 
properties of the neural circuitry underlying FMS with and with-
out comorbid MDD. Customized treatment strategies according 
to pathophysiological features defining FMS subgroups should be 
considered. Multidisciplinary pharmacologic and cognitive be-
havioral approaches are currently viewed as the most effective 
treatments. Drug selection should target the most prominent co-
morbid symptoms, e.g. amitriptyline or pregabalin for those with 
sleep disturbances, duloxetine for those with MDD  [10] . More-
over, the present findings suggest that pharmacologic and psycho-
therapeutic interventions to restore DA regulation may be thera-
peutically beneficial in patients with FMS.
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 Fig. 1. Reward-related changes in regional binding potentials for 
[ 11 C]raclopride. Plot of mean percentage change in binding poten-
tial ( ∆ BP) in the ROI analyses. A significant group difference was 
evident in the right caudate nucleus and the right nucleus accum-
bens. Post hoc tests indicated a significant difference in  ∆ BP be-
tween FMS+ and FMS– patients in the right caudate nucleus and 
between healthy controls and FMS+ patients in the right nucleus 
accumbens. PutL, left putamen; PutR, right putamen; VSTL, left 
ventral striatum; VSTR, right ventral striatum; CNL, left caudate 
nucleus; CNR, right caudate nucleus; NAL, left nucleus accum-
bens; NAR, right nucleus accumbens.  * *   p < 0.05. 
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